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Objective: The patency of small-diameter expanded polytetrafluoroethylene (ePTFE) grafts for vascular reconstruction is
impaired by acute thrombotic occlusion. Prosthetic materials are thrombogenic and cause platelet adhesion and activation of
the coagulation cascade. Heparin is a potent anticoagulant drug widely used to prevent and treat thrombosis. A new ePTFE
graft with long-term bonding of heparin is now commercially available in several European countries, but a basic analysis of
its mechanism of action in humans has never been performed. This study was performed to evaluate the thrombogenicity of
heparin-bonded ePTFE grafts compared with standard ePTFE in a newly developed human ex vivo model.
Methods: Nonanticoagulated blood was drawn from antecubital veins of 10 healthy donors with a 19-gauge needle. The
proximal end of a 60-cm ePTFE vascular graft with a diameter of 3 mm was connected to the needle while the distal end
was connected to a syringe, which was placed in a syringe pump. Every volunteer served as his or her own control by using
a heparin-bonded ePTFE graft on one arm and a standard ePTFE graft on the other arm. The perfusions were performed
over 6 minutes with a flow rate of 20 mL/min, corresponding to a shear rate of 74/s. Serial samples were taken at the
distal end of the graft for determination of prothrombin fragment 1  2, fibrinopeptide A, and P-selectin expression on
perfused platelets. Fibrin deposition and platelet deposition were studied by using scanning electronic microscopy.
Results: Fibrinopeptide A production over time was significantly reduced on the heparin-bonded ePTFE grafts compared
with standard ePTFE grafts (P < .05). There was no increase in the production of prothrombin fragment 1  2 or P
selectin over time on either type of graft. Scanning electronic microscopy scanning showed platelet deposition and fibrin
formation on standard ePTFE grafts, whereas no platelets or fibrin were observed on heparin-bonded ePTFE grafts.
Conclusions: Heparin immobilization substantially reduces the thrombogenicity of small-diameter ePTFE in a newly
developed human ex vivo model. In this study, we provide evidence that the mechanism of action of the heparin bonding
is due not only to anticoagulant but also to antiplatelet effects. Heparin bonding may be an important improvement of
ePTFE, resulting in better patency rates for vascular reconstructions. ( J Vasc Surg 2006;43:587-91.)
Clinical Relevance: Heparin immobilization reduces the thrombogenicity of small-caliber expanded polytetrafluoroeth-
ylene (ePTFE) grafts. The patency of small-diameter ePTFE grafts for vascular reconstruction is impaired by acute
thrombotic occlusion. Prosthetic materials are thrombogenic and cause platelet adhesion and activation of the coagula-
tion cascade. Heparin is a potent anticoagulant drug widely used to prevent and treat thrombosis. A new ePTFE graft
with long-term bonding of heparin is now commercially available, but a basic analysis of its mechanism of action in
humans has never been performed. This study was performed to evaluate the thrombogenicity of heparin-bonded ePTFE
grafts compared with standard ePTFE in a newly developed human ex vivo model. We demonstrated that heparin
immobilization reduces thrombogenicity on small-caliber ePTFE grafts. Heparin-bonded ePTFE grafts might therefore
result in better patency rates for vascular reconstructions with vascular grafts.It is well known that an autologous vein graft is the
surgeon’s first choice in peripheral arterial bypass proce-
dures because of superior patency rates when compared
with prosthetic grafts. In a recent review on venous and
polytetrafluoroethylene (PTFE) above-knee femoropopli-
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doi:10.1016/j.jvs.2005.10.038teal bypasses, 5-year primary patency rates of 74% and 39%,
respectively, were reported.1 However, almost a third of
patients who undergo peripheral arterial reconstructive op-
erations do not have suitable autologous veins available for
grafting.2 Therefore, prosthetic grafts, such as PTFE grafts,
are frequently used in arterial bypass procedures.
Apart from this clinical evidence, laboratory models
also have shown that PTFE grafts are substantially more
thrombogenic compared with autologous veins. Prosthetic
materials cause platelet adhesion and activation of the
coagulation cascade on the graft.3 One potential strategy
for reducing the thrombogenicity of prosthetic material
is to bind heparin to the endoluminal surface. Heparin is a
polysaccharide anticoagulant with potent inhibitory effects
on coagulation and a long history of clinical use in the
prevention and treatment of thrombosis.4 Heparin-bonded
(or heparinized) grafts have shown favorable results in
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cular grafts.5-7 A new expanded PTFE (ePTFE) graft
(GORE-TEX PROPATEN® Vascular graft, W.L. Gore
and Associates, Flagstaff, AZ) with long-term bonding of
heparin accomplished by covalent linkage of the anticoag-
ulant is now commercially available in those European
countries (except France) that accept CE certification. An
in vivo canine study showed measurable heparin activity on
these heparinized ePTFE grafts throughout a 12-week
observation period, with only a marginal drop in activity
after 12 weeks.5 These results indicate that this particular
heparin immobilisation method yields grafts that express
anticoagulant properties for prolonged periods after im-
plantation. Although the anticoagulant mechanism of ac-
tion of intravenous heparin is well established, little is
known about the precise mechanisms by which immobili-
zation of heparin on vascular grafts reduces the thrombo-
genicity of ePTFE in humans. In this study we evaluated
the potential mechanism of action by analysis of the throm-
bogenicity of standard ePTFE and heparinized ePTFE
grafts by a comprehensive investigation of clotting param-
eters and deposition of platelets and fibrin in a newly
developed human ex vivo model.
METHODS
Ex vivo model. In a newly developed ex vivo model,
nonanticoagulated blood was drawn from the antecubital
veins of 10 healthy donors with a 19-gauge needle. A
60-cm vascular graft with a diameter of 3 mm was directly
connected to the needle (Fig 1). During 6 minutes, the blood
was aspirated with a constant flow rate of 20 mL/min by
using a syringe pump (Harvard Apparatus, South Natick,
Mass). This flow rate and graft diameter result in a shear rate
of 74/s, which reflects venous flow conditions and favors
fibrin-rich clot formation. A cuff was wrapped around the
upper arm to ensure a constant pressure of 45 mm Hg,
resulting in a continuous blood flow through the graft during
the experiment. Volunteers denied taking any medication 2
weeks before the experiment and gave informed consent.
Every volunteer served as his or her own control. In the
first run, a standard Gore-Tex (W. L. Gore & Associates,
Inc, Flagstaff, Ariz) ePTFE graft was perfused by using
blood drawn from one arm. In the second run, which was
performed within half an hour of the first, a Gore-Tex
ePTFE graft treated with Carmeda BioActive Surface
(CBAS) technology was perfused with blood drawn from
the other arm. CBAS is a clinically used heparin-binding
technology. This technology is based on covalent end-
point attachment of heparin to a biomaterial surface, thus
enabling maintenance of functional heparin bioactivity.
Heparin-bonded ePTFE grafts. Standard ePTFE
Gore-Tex vascular grafts (internal diameter, 3 mm; length,
60 cm) were used in our study. The luminal microstructure
of the heparinized grafts was treated with the CBAS, in
which heparin molecules are covalently bound via end-
point aldehyde linkages to free amino groups in an under-
lying polyethyleneimine sublayer. End-point attachment
permits the pentasaccharide active sites on the heparin toremain available for binding antithrombin III. The proce-
dure to modify heparin with free aldehyde moieties has
been described previously.5,6 Standard nonheparinized
ePTFE grafts were steam-sterilized; heparinized ePTFE
grafts were sterilized with ethylene oxide.
Blood samples and assays. Blood samples (900 L)
were collected at the end of the graft, starting directly after
connection to the vein and thereafter every minute until 4
minutes. After 4 minutes, samples were collected every 30
seconds until the end of the perfusion (total perfusion time, 6
minutes per arm). The samples were mixed immediately with
100 L of ethylenediaminetetraacetic acid (500 mmol/L)
and centrifuged at 3500 rpm for 5 minutes, and aliquots of
plasma were stored at 20°C until assayed.
A commercially available enzyme-linked immunosor-
bent assay was used for the fibrinopeptide A (FPA) mea-
surements as an indicator of fibrin formation (Zymutest
FPA; Hyphen Biomed, Andresy, France). Prothrombin frag-
ment 1 2 (F12), an indicator of thrombin formation, was
also measured by using an enzyme-linked immunosorbent
assay (Enzygnost–F12; Dade Behring, Marburg, Germany).
P-selectin expression on perfused platelets, as an indicator
of activation of platelets, was determined in whole blood
(nonanticoagulated blood). Blood was collected in parafor-
maldehyde (4%) by flow cytometry analysis by using an
R-phycoerythrin–conjugated monoclonal antibody ac-
cording to the instructions of the manufacturer (Dako,
Glostrup, Denmark; code R7200).
Scanning electron microscopy. The deposition of
platelets and fibrin onto the grafts was visualized by scan-
ning electron microscopy. The distal end of the graft was
cut into small pieces (5  5 mm), fixed in 2% glutaralde-
hyde, and then dehydrated through increasing concentra-
tions of ethanol (80%-100%). The samples were dried with
the use of hexamethyldisilazane. Next, ePTFE pieces were
Fig 1. The newly developed ex vivo perfusion system using a cuff
at a constant pressure of 45 mmHg to ensure blood flow. Blood is
aspirated through the graft with a constant flow of 20 mL/min,
resulting in a shear rate of 74/s.sputter-coated with a thin layer of platinum/palladium and
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Eindhoven, The Netherlands).
Statistical analysis. Results are expressed as themean
SEM. A paired t test was used to determine the significance
of differences between groups. A P value of .05 was
considered significant.
RESULTS
In our newly developed ex vivo model, nonanticoagu-
lated blood was drawn directly from the antecubital veins
over either standard Gore-Tex ePTFE vascular grafts or
grafts to which heparin was covalently bonded by means of
CBAS technology. All 10 perfusions were performed with-
out any complications, concerning the volunteers as well as
the setup itself.
On standard grafts, platelet deposition and fibrin
Fig 2. Scanning electron microscopy showing platelet
Gore-Tex expanded polytetrafluoroethylene vascular graf
(A) and no such adhesion or deposition on theGore-Tex
Representative pictures of a single volunteer are shown.
Fig 3. Heparin immobilization reduces fibrin formation during ex
vivo perfusions. Perfusions were performed in 10 volunteers by using
both a noncoated and heparin-bonded graft in each volunteer. Serial
samples were taken during perfusion, in which levels of fibrinopeptide
A (FPA) were measured by enzyme-linked immunosorbent assay.
Error bars indicate SEM. ePTFE, Expanded polytetrafluoroethylene.formation were observed by scanning electron micros-copy, whereas on heparinized grafts, no platelets or fibrin
deposits were observed (Fig 2). On standard grafts, a
progressive increase in the production of FPA was ob-
served in time. FPA production on the heparinized grafts
was substantially depressed compared with the standard
grafts. A significant difference in FPA values between
standard and heparinized grafts was observed at 5 min-
utes and later (Fig 3).
No increase in F12 levels in time was observed on
either graft (Fig 4) nor was an increase of P-selectin expres-
sion in time noted on platelets in the perfusate of either
graft (Fig 5).
DISCUSSION
In this study, we evaluated in a novel ex vivo setup the
thrombogenicity of small-diameter (3-mm) ePTFE grafts
esion and fibrin deposition (arrows) on the untreated
used for 6 minutes with nonanticoagulated whole blood
treated with Carmeda BioActive Surface technology (B).
Fig 4. Progression of prothrombin fragment 1  2 (F12) levels
in the perfusate over time. There was no increase in F12 in the
perfusate over time on either type of vascular graft, thus indicating
that no measurable amount of thrombin was generated. Error bars
indicate SEM. ePTFE, Expanded polytetrafluoroethylene.adh
t perf
grafttreated with CBAS technology compared with standard
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model, in contrast with other ex vivo models, is that the
blood of the volunteer does not come into contact with
surfaces other than the materials investigated. In this setup,
every volunteer was his or her own control.
We assessed the standard untreated ePTFE always in the
first run. We hypothesized that if there was any in vivo activa-
tion of the coagulation cascade as a consequence of the
procedure after the first run, the outcome of the second run
might be influenced. Therefore the condition in which inhi-
bition of thrombogenicity was anticipated was always per-
formed last. However, we did not observe any differences in
baseline F12 and FPA levels in the first and second run,
indicating that systemic coagulation activation by the proce-
dure is unlikely. Moreover, we did observe a substantially
decreased production of FPA by heparinized grafts in the
second run, indeed indicating that thrombogenicity of hepa-
rinized grafts is reduced. If an unmeasurable activation of
hemostasis was present after the first run, the results of this
study might even be underestimated.
We found a substantial reduction in thrombogenicity of
the ePTFE grafts as a result of the heparin bonding. Platelet
adhesion and fibrin deposition were observed only on the
surface of the standard grafts. Moreover, a significant reduc-
tion in FPA production was observed on heparinized grafts
when comparedwith standard grafts. Therewas no increase in
F12 in the perfusate over time on both types of vascular
grafts, thus indicating that no measurable amount of throm-
binwas generated. P-selectin expressionon the perfusedplate-
lets did not increase over time on either graft surface, thus
indicating that no measurable amount of platelets was acti-
vated.
The discrepancy between the increase in FPA levels and
the absence of significant F12 production can be explained
by the fact that one single thrombin molecule cleaves many
fibrinogen molecules into fibrin. Apparently, the amount of
thrombin generated is too small to be detected by the F12
assay used.
In a recently published study by Keuren et al.,8 comparing
Fig 5. Progression of the percentage of P-selectin–positive plate-
lets (pos plts) in the perfusate over time. P-selectin expression on
the perfused platelets did not increase over time on either graft
surface, thus indicating that no measurable number of platelets
was activated. Error bars indicate SEM. ePTFE, Expanded
polytetrafluoroethylene.heparinized and nonheparinized collagen surfaces, it wasnoted that thrombin activity became detectable after 12 min-
utes, and peaked after 20 minutes.8 In contrast with our study,
these experiments were performed with recalcified anticoagu-
lated blood. The time course of coagulation in this more or
less artificial system will be different from the time course in
vivo or in our ex vivo experiments. Although detectable
thrombin generation might have occurred with longer perfu-
sion times, this was not feasible due to the substantial amounts
of blood that were used in this experiment (2 times 120mLof
blood was drawn). The clinical extrapolation of our results
might therfore be limited to the mechanism of action by
which the heparinized graft reduces acute graft thrombosis,
although the mechanism by which delayed thrombosis is
accomplished is presumably highly similar.
The fact that P-selectin expression did not increase over
time on either graft surface may be explained by the limited
perfusion time in this model. During the 6 minutes of perfu-
sion, only a small percentage of platelets became activated as a
result of the platelet-activating properties of ePTFE. These
activated platelets are able to adhere to the graft surface, as
shown by scanning electronmicroscopy. It is conceivable that
the platelets that are activated by ePTFE also adhere to the
graft; this would explainwhy no activated platelets were found
in the blood collected at the distal end of the graft.
Two potential mechanisms may be responsible for the
reduced thrombogenicity of the heparinized grafts. First, the
bondedheparin reduces the formationof thrombinbecause of
the inhibition of coagulation. As a result, both fibrin forma-
tion and thrombin-mediated platelet activation are dimin-
ished. Second, the negatively charged surface directly prevents
platelet interaction with the graft because of electrostatic
repulsion, because the net charge of the platelet is also nega-
tive.9 The phenomenon of reduction of platelet adhesion by
using covalent heparin immobilization has not been shown in
humans before.
Because the patency of small-diameter ePTFE grafts for
vascular surgery is impaired by graft occlusion due to acute
thrombosis, the application of the CBAS technology to vas-
cular grafts may reduce this acute problem. This study is the
first to prove that thrombogenicity is reduced in a human ex
vivo model using the CBAS technology on Gore-Tex ePTFE
vascular grafts. In concordancewith our results, a recent study
on small-caliber CBAS heparin-coated ePTFE grafts showed
significantly reduced platelet deposition in arterial grafts in
baboons.5 In addition, a reduction of anastomotic neointimal
hyperplasia and cell proliferation, without measurable side
effects, was observed. A recently published prospective ran-
domized trial described patients with femoropopliteal bypass
by using a different kind of heparin-bonding technique on
vascular grafts. The authors showed significantly increased
patency rates after 3 years of follow-up and a reduced inci-
dence of major limb amputation compared with non–hepa-
rin-bonded vascular grafts.7
In conclusion, heparin bonding reduces the thromboge-
nicity of ePTFE grafts. Here we provide evidence that the
mechanismof action of the heparin bonding is due not only to
anticoagulant but also to antiplatelet effects.Heparin bonding
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better patency rates for vascular reconstructions.
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